Literature DB >> 26084513

Seropositivity for Antibodies to DRS-G, a Virulence Factor from Streptococcus dysgalactiae subsp. equisimilis, Is an Independent Risk Factor for Poststreptococcus Glomerulonephritis and Chronic Kidney Disease in Mumbai, India.

Gouri P Hule1, Mohan G Karmarkar1, Ainslie Cameron2, Niwrutti Hase1, Uday Khopkar1, Preeti R Mehta1, Celia L McNeilly3, David McMillan4, Kadaba S Sriprakash5.   

Abstract

The disease spectrum caused by Streptococcus dysgalactiae subsp. equisimilis resembles that of S. pyogenes (group A streptococcus [GAS]). These two bacterial species are closely related and possess many common virulence characteristics. While some GAS strains express virulence factors called streptococcal inhibitor of complement (SIC) and distantly related to SIC (DRS), some S. dysgalactiae subsp. equisimilis isolates express an orthologue of DRS, which is referred to as DRS-G. We reported previously that seropositivity for either anti-SIC or anti-DRS antibodies (Abs) is associated with poststreptococcal glomerulonephritis (PSGN). However, only seropositivity for anti-SIC Abs is associated with chronic kidney disease (CKD). We now extend the study to test whether seropositivity for anti-DRS-G Abs is also associated with these renal diseases. Stored serum samples collected for our previous study were tested by an enzyme-linked immunosorbent assay (ELISA) for Abs to DRS-G. The samples represented sera from 100 CKD adult patients, 70 adult end-stage renal disease (ESRD) patients, 25 PSGN pediatric patients, and corresponding age-matched control subjects. The proportion of PSGN, CKD, and ESRD patients who showed seroreaction to anti-DRS-G Abs was significantly higher than that of the corresponding age-matched controls, who in general exhibited seropositivity rates commensurate with the isolation rate of drsG-positive S. dysgalactiae subsp. equisimilis in the community during this study period. Since higher rates of seropositivity for anti-DRS-G Abs in the renal disease categories are resultant of previous infections with DRS-G-positive S. dysgalactiae subsp. equisimilis strains, we conclude the seropositivity is an additional risk factor for these renal diseases. In this regard, anti-DRS-G Abs have attributes similar to those of the anti-SIC Abs.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26084513      PMCID: PMC4519730          DOI: 10.1128/CVI.00275-15

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  24 in total

1.  Streptococcal inhibitor of complement (SIC) inhibits the membrane attack complex by preventing uptake of C567 onto cell membranes.

Authors:  B A Fernie-King; D J Seilly; C Willers; R Würzner; A Davies; P J Lachmann
Journal:  Immunology       Date:  2001-07       Impact factor: 7.397

2.  Antibodies to streptococcal inhibitor of complement function and M peptides in a post-streptococcal glomerulonephritis endemic region of Australia.

Authors:  K S Sriprakash; Jon Hartas; Andrew White
Journal:  J Med Microbiol       Date:  2002-07       Impact factor: 2.472

3.  Attribution of the various inhibitory actions of the streptococcal inhibitor of complement (SIC) to regions within the molecule.

Authors:  Michael J Binks; Barbara A Fernie-King; David J Seilly; Peter J Lachmann; Kadaba S Sriprakash
Journal:  J Biol Chem       Date:  2005-03-15       Impact factor: 5.157

4.  Acute glomerulonephritis following group G streptococcal infection.

Authors:  J W Gnann; B M Gray; F M Griffin; W E Dismukes
Journal:  J Infect Dis       Date:  1987-08       Impact factor: 5.226

5.  Community-wide outbreak of group G streptococcal pharyngitis.

Authors:  M A Gerber; M F Randolph; N J Martin; M F Rizkallah; P P Cleary; E L Kaplan; E M Ayoub
Journal:  Pediatrics       Date:  1991-05       Impact factor: 7.124

6.  The interaction of streptococcal inhibitor of complement (SIC) and its proteolytic fragments with the human beta defensins.

Authors:  Barbara A Fernie-King; David J Seilly; Peter J Lachmann
Journal:  Immunology       Date:  2004-04       Impact factor: 7.397

7.  Protein SIC, a novel extracellular protein of Streptococcus pyogenes interfering with complement function.

Authors:  P Akesson; A G Sjöholm; L Björck
Journal:  J Biol Chem       Date:  1996-01-12       Impact factor: 5.157

8.  Streptococcal inhibitor of complement inhibits two additional components of the mucosal innate immune system: secretory leukocyte proteinase inhibitor and lysozyme.

Authors:  Barbara A Fernie-King; David J Seilly; Alexandra Davies; Peter J Lachmann
Journal:  Infect Immun       Date:  2002-09       Impact factor: 3.441

9.  Characterization of a complement-binding protein, DRS, from strains of Streptococcus pyogenes containing the emm12 and emm55 genes.

Authors:  Michael Binks; K S Sriprakash
Journal:  Infect Immun       Date:  2004-07       Impact factor: 3.441

10.  Group G streptococcal bacteremia in Jerusalem.

Authors:  Ronit Cohen-Poradosu; Joseph Jaffe; David Lavi; Sigal Grisariu-Greenzaid; Ran Nir-Paz; Lea Valinsky; Mary Dan-Goor; Colin Block; Bernard Beall; Allon E Moses
Journal:  Emerg Infect Dis       Date:  2004-08       Impact factor: 6.883

View more
  1 in total

1.  In vitro and in vivo study of the expression of the Syk/Ras/c‑Fos pathway in chronic glomerulonephritis.

Authors:  Jiarong Gao; Liangbing Wei; Junmei Song; Hui Jiang; Yachen Gao; Xi Wu; Shuangzhi Xu
Journal:  Mol Med Rep       Date:  2018-08-03       Impact factor: 2.952

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.